NEW YORK (TheStreet) --
Acme United was downgraded to hold at TheStreet Ratings.
Alexion was initiated with a neutral rating at Credit Suisse. $110 price target. Company lacks near-term catalysts, Credit Suisse said.
Biomarin was initiated with a neutral rating at Credit Suisse. Valuation call, based on a $68 price target, Credit Suisse said.
Clearwire was upgraded at DA Davidson to neutral from underperform. $4.40 price target. Expect Sprint Nextel to match DirecTV's bid.
Cepheid was downgraded at Jefferies to hold from buy. Valuation call, based on a $38 price target, Jefferies said.
Calpine was upgraded at Deutsche Bank to buy from hold. $23 price target. Rising interest rates make company an attractive choice, relative to traditional utilities, Deutsche Bank said.
Exterran was upgraded to buy at TheStreet Ratings.
Haemonetics was initiated with a neutral rating at Goldman Sachs. Valuation call, based on a $47 price target, Goldman said.
Mellanox was downgraded at UBS to neutral. TASE delisting and the potential split of the CEO and chairman roles will drive near-term pressure, UBS said. Price target is now $57.
Morgan Stanley was upgraded at Deutsche Bank to buy from hold. $30 price target. Stock continues to trade at a discount to tangible book value, even though earnings momentum appears poised to accelerate, Deutsche said.
Myriad was downgraded at Jefferies to hold from buy. $31 price target. Stock is up more than 20%, ahead of the pending Supreme Court decision, Jefferies said.
Northwestern was upgraded at Robert Baird to outperform from neutral. $47 price target. Natural gas acquisition should boost earnings growth, Baird said.
RF Micro was upgraded at DA Davidson to buy from neutral. Estimates were also increased as the company can expand its gross margin, DA Davidson said.
Scotts Miracle-Gro was downgraded at BMO Capital to underperform from market perform. Valuation call, based on a $43 price target, BMO Capital said.
Tiffany was initiated with an outperform rating at Credit Suisse. $89 price target. Company can deliver low-teens annual earnings growth over the next five years, Credit Suisse said.
STOCK COMMENTS / EPS CHANGES
BioMarin price target was raised at Citigroup to $79. Anticancer drug BMN-673 was included in the model, said Citigroup.
CBS price target was boosted at Bank of America/Merrill Lynch. Shares are now seen reaching $60. Monetizing the outdoor business should be accretive to earnings, BofA/Merrill said. Buy rating.
CIT Group numbers were increased at Credit Suisse through 2015. Expect an accelerated capital return this year, Credit Suisse said. Neutral rating and new $44 price target.
Costco estimates, price target were increased at Jefferies. Estimates were raised through 2014. Higher membership fees are driving sales growth, Jefferies said. Hold rating and new $101 price target.
Costco price target was raised at UBS to $124. Reflects increasing membership fees and faster unit growth, said UBS. Earnings estimates were also tweaked.
Dollar General estimates were reduced at Citigroup. Earnings estimates were lowered given the impact of cool weather on seasonal and discretionary items, said Citigroup.
Ford price target was raised at Sterne Agee. Shares are now seen reaching $19. Company can increase cash returns with record earnings, Sterne Agee said. Buy rating.
General Motors price target was boosted at Sterne Agee. Shares are now seen reaching $46. North American auto trends continue to improve, Sterne Agee said. Buy rating.
Joy Global estimates were reduced at UBS. Reflects the guidance cut from mining capex headwinds, said UBS.
Palo Alto Networks numbers were reduced at Credit Suisse. Shares are now seen reaching $57.50. Estimates also cut, as the company is seeing lower product revenue, Credit Suisse said. Outperform rating.
Palo Alto Networks price target was lowered at UBS to $55. Reflects increased macro sensitivity, said UBS.
JM Smucker numbers were increased at Jefferies. Shares are now seen reaching $98. Estimates were also increased, given continued momentum in the consumer space, Jefferies said. Hold rating.
Splunk estimates, price target were raised at Credit Suisse. Shares are now seen reaching $50. Estimates also increased, as the company continues to sign more big deals, Credit Suisse said. Outperform rating.
>To submit a news tip, email: firstname.lastname@example.org.